PREVIOUS
✖
COVID 19 drug - Sepsivac
April 24 , 2020
1679 days
1008
0
- The Drugs Controller General of India (DCGI) approved the trial of this drug to reduce mortality rate of COVID-19 patients.
- It was developed by the Cadila Pharmaceuticals along with Council of Scientific and Industrial Research (CSIR).
- The drug had been used to treat critically ill patients suffering from Gram Negative Bacterial Sepsis.
- Gram Negative Bacteria with Sepsis is a systematic disease that are caused by micro-organisms.
- The patients suffering from COVID-19 and Gram Negative Bacterial Sepsis have similarities.
- Sepsis is a life-threatening condition.
- When the chemicals in the bloodstream go out of balance, sepsis occurs.
Leave a Reply
Your Comment is awaiting moderation.